Targeting Donor Dendritic Cell Subsets Prevents Lethal Gut Graft-Versus-Host Disease in Mice

Acute graft-versus-host disease remains a primary obstacle to successful allogeneic hematopoietic stem cell transplantation, as the required lifelong immunosuppression can negatively affect long-term graft and patient survival [1]. While cell-based therapies such as mesenchymal stromal cells (multipotent cells that alter cytokine profiles to induce an anti-inflammatory phenotype) have been explored, the risk of treatment-related toxicity and infection remains a clinical priority [2, 3]. In a phase I/IIa clinical trial involving 13 patients with hematologic malignancies, a single infusion of donor early apoptotic cells at doses of 140 or 210 × 10^6 cells/kg resulted in a 0% incidence of grade II to IV acute graft-versus-host disease, compared to a 23% incidence across all dose groups [4]. Gastrointestinal involvement is particularly severe, as dysregulated production of interleukin-6 (a cytokine that stimulates acute phase responses) drives rapid tissue damage and early transplant mortality [5, 6]. New research indicates that donor XCR1+ conventional dendritic cells (specialized antigen-presenting cells) are essential for initiating Th1-mediated gut damage, while CD11b+ dendritic cells drive Th17-dependent inflammation [6]. Identifying these distinct cellular mechanisms is critical for developing targeted prophylactic regimens that preserve the delicate balance between immune tolerance and antimicrobial immunity [7, 6].